- In an Inter Partes Review, the USPTO's Patent Trial and Appeals Board (PTAB) upholds five Mallinckrodt (NYSE:MNK) patents covering INOMAX (nitric oxide) gas for inhalation. The patents, valid until 2031, were challenged by Praxair Distribution (PX).
-
INOMAX is approved in the U.S. to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation in term and near-term (at least 34 weeks gestation) neonates with hypoxic respiratory failure associated with pulmonary hypertension in conjunction with ventilator support and other agents.